MarketInOut Stock Screener Log In | Sign Up
 

Prothena Corp Plc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Prothena Corp Plc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization424.04 mln
Float44.60 mln
Earnings Date10/29/2026

Piotroski F-Score

6 / 9
Solid

Beneish M-Score

1.93
Highly suspicious

Relative Strength

30 / 100
Underperforming

Debt / Equity

0.02
Debt-free

Pre-Tax Margin

-81%
Severely loss-making

ROE

-14.67
Negative

Business Description

Prothena Corporation plc is an Irish biotechnology company founded in 2012 and headquartered in Dublin, focused on developing treatments for serious diseases caused by abnormal protein behavior in the body. The company has a broad pipeline of experimental medicines targeting conditions such as Parkinson's disease, Alzheimer's disease, and other neurological disorders, with several candidates currently in advanced clinical trials. Prothena works alongside major pharmaceutical partners, including Roche and Bristol Myers Squibb, to advance and commercialize these therapies on a global scale.

Key Fundamentals

EPS-0.82
ROE-14.67
RPS1.02
ROIC-150
ROA-12.71
EBITDA, mln-40.63
EV / EBITDA-3.76
EV / EBIT-3.45
Revenue, mln54.53
EV / Revenue2.80

Quote Details

Last 8.20
Change -0.05 (-0.61%)
Open 8.18
Volume 385,913
Turnover 3,164,486
Average Volume 551,919

Financial Ratios

Pre-Tax Profit Margin-81
Leverage Ratio1.05
Current Ratio25.05
Price / Book1.51
Price / Tangible Book1.51
Debt / Equity0.02
Price / Sales8.32

Financial Strength

Altman Z-Score11.88
Piotroski F-Score 6 / 9
Beneish M-Score1.93
Short Ratio17.58
Short % of Float18.79

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -1.8% 28 / 100   
1 Month -1.44% 54 / 100   
2 Months -5.42% 40 / 100   
6 Months -23.72% 24 / 100   
1 Year -17% 32 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog